FibroBiologics Announces Advances in Burn Treatment Using Proprietary Fibroblast Spheroid Technology

About this update from Fibrobiologics, Inc.

[{"type":"text","content":"HOUSTON, March 12, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using proprietary fibroblast spheroid technology, today announced the expansion of its wound care platform into the treatment of patients with acute and chronic burn injuries. Building on its investigational fibroblast spheroid-based programs in chronic wound healing, FibroBiologics is applying the same core technology to address the significant unmet medical needs in burn care, where current standards of care often result in prolonged healing, multiple procedures, and substantial scarring. In preclinical burn models, treatment with proprietary fibroblast spheroids (CYWC628) was associated with nearly a four-fold increase in tissue-level IL-10, a cytokine known to support tissue repair and wound healing in skin.​Additionally, CYWC628 drove a significant reduction in IL-1B, a key driver of inflammation in burn wounds, further supporting the potential of the platform to promote better, faster healing in patients with severe burns.​These findings suggest that CYWC628 may both accelerate wound closure and improve the quality of healed tissue by simultaneously promoting regeneration and dialing down harmful inflammation.​ “These new burn data reinforce our conviction that fibroblast spheroids can reshape how serious wounds are treated,” said Pete O’Heeron, Founder and Chief Executive Officer of FibroBiologics. “By combining strong signals of tissue repair with meaningful reductions in inflammatory markers, CYWC628 positions us to address a large, underserved market in burn care and create significant benefit for patients. We believe that a targeted, cell-based approach has the potential to improve healing outcomes, reduce complications, and ultimately change the standard of care for burn patients worldwide.”​ “From a scientific standpoint, seeing nearly a four-fold increase in IL-10 alongside a significant reduction in IL-1B in burn tissue is highly encouraging,” noted Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “These tissue-level biomarker changes align with the type of regenerative, pro-healing environment we are aiming to create in complex wounds and...

More updates from Fibrobiologics, Inc.